About CJC-1295 Pharmacy

What this site is

CJC-1295 Pharmacy is a dossier — a two-register reading of what the published record says about CJC-1295. It keeps no clinic and no clinical staff, writes no prescriptions, and offers no dose or diagnosis; there is no counter here to fill a script at, and nothing on the page is for sale. What it does is read the papers and mark where each claim came from.

The 'pharmacy' in the domain name names a vantage point, not a service the site performs. CJC-1295 moves through compounding pharmacies across the United States in real volume, and the writing about it falls into two piles: a slim peer-reviewed canon — one Phase I human trial, two foundational rodent studies, a structural-biology paper, a class-comparator tesamorelin trial — and a far thicker gray literature of product sheets, clinic marketing, and direct-to-consumer protocol guides. The dossier sets both on the same page and tells them apart by typography: solid rules around peer-reviewed evidence, dashed rules around gray-literature claims.

Origin and development

Origin and development

CJC-1295 was developed by ConjuChem in the early 2000s as a long-acting GHRH-analog drug candidate ^[13]. The Phase II HIV-lipodystrophy trial (192 participants) was halted in 2006 following a participant death from myocardial infarction; the investigator attributed the event to pre-existing asymptomatic coronary artery disease rather than to study drug, but commercial development was discontinued. The molecule has persisted since in compounding-pharmacy use and a thin academic literature.

Editorial method

The dossier method is straightforward. Every quantitative claim on every page maps to a numbered citation in the references table. Peer-reviewed primary research — the Teichman 2006 Phase I trial, the Jetté 2005 albumin-bioconjugate characterization, the Alba 2006 GHRH-knockout mouse rescue — is set inside solid rules and carries the canonical authority of the published Phase I record. Compounding-pharmacy gray literature — the 100-300 µg total-daily protocols, the 'CJC-1295 + ipamorelin' product sheets, the clinic marketing language — is set inside dashed rules and is labeled as such.

The distinction between the two registers is the load-bearing editorial commitment of the site. No saturated color, no alarm chips, no shouting — the typography does the categorical work. A reader who scans the page and sees a dashed perimeter or a dashed left rule on a callout knows immediately that what sits inside is a claim from the compounding-pharmacy literature, not a finding from a peer-reviewed trial.

We do not invent citations. We do not invent dose recommendations. We do not refer to 'our doctors' or 'our pharmacists' or any implied healthcare staff. The dossier is a reading of publicly available science, set in Playfair Display and Manrope, organized by a structural numeral system, and bound to no commercial relationship with any compounder, vendor, or clinic.

What we publish and what we do not

What we publish: editorial summaries of the published CJC-1295 record, organized by topic (mechanism, pharmacokinetics, Phase I outcomes, side effects, regulatory posture, class context). We publish a frequently-asked-questions index, a full references table, and short dedicated landing pages for the two highest-traffic informational keywords (CJC-1295 dosage and CJC-1295 side effects).

What we do not publish: dose recommendations, treatment protocols, vendor reviews, telehealth referrals, prescription information, or any content that could be read as medical advice. We do not link to other portfolio domains. We do not run advertising for compounders, clinics, or peptide vendors. The site is editorial — a quiet research record, not a commercial pharmacy.